This site is intended only for all Healthcare Professionals residing in South Africa
Patients receiving SUTENT® (sunitinib) show an almost four-fold increase in time to disease progression compared with those randomised to placebo.1
When corrected for crossover (RPSFT method)* SUTENT® (sunitinib) nearly doubled mOS compared with placebo1
Patients continue to benefit from treatment with SUTENT® (sunitinib) even after progression2
Phase III international randomised double-blind trial evaluating SUTENT® (sunitinib) in GIST patients after imatinib failure. 361 patients randomized to either sunitinib (n=243) or placebo (n=118) with: histologically proven GIST who had failed imatinib treatment due to resistance or intolerance, ECOG PS ≤1 and adequate hepatic, renal, and cardiac function. Patients were randomized 2:1 to receive treatment in repeated 6-week cycles of 4 weeks of daily sunitinib (50 mg) or placebo followed by 2 weeks off treatment.1
A worldwide, open-label, treatment-use study of imatinib-refractory or - intolerant GIST. 1131 patients enrolled; 1124 patients comprised the ITT population. In this post-hoc analysis, patients were stratified based on whether SUTENT® (sunitinib) treatment was continued (n=380) or stopped (n=324) after objective assessment of progressive disease. Treatment continued as long as there was evidence of disease control. Survival was monitored for up to 2 years after the last dose.2
Copyright ©2023 Pfizer South Africa All rights reserved.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.
This website is brought to you by Pfizer South Africa
Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).
Copyright © 2023. Pfizer Laboratories (Pty) Ltd. All rights reserved
These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.
I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.